{
    "id": 17417,
    "fullName": "IL6 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "IL6 over exp indicates an over expression of the Il6 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3569,
        "geneSymbol": "IL6",
        "terms": [
            "IL6",
            "BSF-2",
            "BSF2",
            "CDF",
            "HGF",
            "HSF",
            "IFN-beta-2",
            "IFNB2",
            "IL-6"
        ]
    },
    "variant": "over exp",
    "createDate": "01/31/2016",
    "updateDate": "01/31/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4304,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sylvant (siltuximab) inhibited proliferation of human leukemia cell lines stimulated with IL6 in culture (PMID: 26744529).",
            "molecularProfile": {
                "id": 17710,
                "profileName": "IL6 over exp"
            },
            "therapy": {
                "id": 3485,
                "therapyName": "siltuximab",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4303,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 inhibited proliferation of human leukemia cell lines stimulated with IL6 in culture (PMID: 26744529).",
            "molecularProfile": {
                "id": 17710,
                "profileName": "IL6 over exp"
            },
            "therapy": {
                "id": 3481,
                "therapyName": "MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4296,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MEDI5117 inhibited the growth of human IL6-stimulated prostate cancer cells with IL6R and IL6 expression in culture and inhibited tumor growth in xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 20372,
                "profileName": "IL6 over exp IL6R pos"
            },
            "therapy": {
                "id": 3481,
                "therapyName": "MEDI5117",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4302,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sylvant (siltuximab) inhibited the growth of IL6-stimulated human prostate cancer cells with IL6 and IL6R expression in culture and inhibited tumor growth in cell line xenograft models (PMID: 26744529).",
            "molecularProfile": {
                "id": 20372,
                "profileName": "IL6 over exp IL6R pos"
            },
            "therapy": {
                "id": 3485,
                "therapyName": "siltuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4491,
                    "pubMedId": 26744529,
                    "title": "A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26744529"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17710,
            "profileName": "IL6 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17711,
            "profileName": "IL6 over exp IL6R wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18648,
            "profileName": "ERBB2 amp IL6 over exp IL6R pos PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20372,
            "profileName": "IL6 over exp IL6R pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}